Ensysce Biosciences @EnsysceBio1

With a dual-market strategy, Ensysce is addressing a $3.8B opportunity in U.S. pain management, including acute ($1.6B) and chronic ($2.2B) pain segments. 🔹 PF614: Targeting acute severe pain, delivering superior pain control for a limited duration. 🔹 PF614-MPAR: Designed for…

How is the Ensysce Solution Different? $ENSC Ensysce’s platforms use chemical safety switches designed to transform pain treatment: 🔹 TAAP™ (Trypsin-Activated Abuse Protection): Reduces abuse risk by controlling activation and release. 🔹 MPAR® (Multi-Pill Abuse Resistance):…

📸 Live from PAINWeek 2025 Dr. Jeff Gudin, University of Miami Pain Center, examined the latest entrants to the analgesic toolbox—including NAV 1.8 inhibitors—and compared them to Ensysce’s Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®)…

📸 Live from PAINWeek 2025 Dr. William Schmidt, Chief Medical Officer of Ensysce, presented to a packed room of 400+ pain experts on the promise of PF614 (TAAP™) and PF614-MPAR®. Dr. William Schmidt shared compelling data differentiating PF614 from other severe pain…

Last week, Ensysce Biosciences participated in PAINWeek, the largest pain conference in the world, where experts meet to share knowledge to enhance patient care. Moderated by Dr. Lynn Kirkpatrick, CEO of Ensysce, the event brought together three leading authorities in pain…

$ENSC Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium View key takeaways from its standing-room-only symposium, “Pain Management, RE-Invented: A New Era for Analgesia”, held September 3, 2025, at PAINWeek in Las Vegas—the world’s largest…

📢 Tomorrow at PAINWeek 2025 Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, will speak at PAINWeek — the largest pain conference in the world. 🔹 Symposium: “Pain Management, RE-Invented: A New Era for Analgesia” 🔹 Date: September 3, 2025, at 12 noon PT. 🔹…

Next Week: @PAINWeek is the largest pain conference in the world, where experts meet to share knowledge to enhance patient care. The Ensysce Biosciences-sponsored symposium ‘Pain Management, RE-Invented: A New Era for Analgesia' will take place in Las Vegas on September 3rd,…

Ensysce Biosciences August 2025 Investor Presentation - Clinical Momentum & Strategic Roadmap - Advancing PF614 toward a pivotal Phase 3 program - PF614-MPAR is in an active Phase 1b program - Platform strategy: TAAP™ (anti-abuse) + MPAR® (overdose protection) with a 505(b)(2)…

$ENSC Ensysce Biosciences’ Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 ~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma…

$ENSC Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates - Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval - Receives $5.3 Million Installment from NIDA…

“We target the toughest diseases where suffering is high and abuse or overdose can be an issue. Our mission is simple: reduce suffering using advanced technologies.” Quote from Geoff Birkett, Chief Commercial Officer $ENSC #EnsysceBiosciences

Our pipeline is based on 2 key technologies. TAAP™ controls how our products are activated and released to improve performance and safety. MPAR® can turn off the activation if too much medication is consumed, thereby protecting from overdose. Our development pipeline of…

The development of Ensysce’s PF614-MPAR has been supported by two multi-year grants from the National Institute on Drug Abuse (NIDA). The most recent grant was awarded in 2024 and will continue to fund the program through May 2027. This support reflects the ongoing alliance…

@EnsysceBio1 is working to highlight the safety benefits of PF614-MPAR, with a successful meeting with the @FDA that discussed its continued development. The constructive guidance included discussions regarding collaborating to produce a whitepaper on its Overdose Protection.…

$ENSC Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback ~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~ ~ FDA and Ensysce Aligned on Collaborative…

Save The Date: @PAINWeek is the largest pain conference in the world, where experts meet to share knowledge to enhance patient care. The Ensysce Biosciences-sponsored symposium ‘Pain Management, RE-Invented: A New Era for Analgesia' will take place in Las Vegas on September 3rd,…